Catalyst Pharmaceuticals Inc share price logo

Catalyst Pharmaceuticals Inc Share Price

NASDAQ: CPRX

Mid Cap

$23.93

-1.13

(-4.53%)

as on

Catalyst Pharmaceuticals Inc Stock Performance

as on February 6, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $23.86
    $25.40
    downward going graph

    0.29%

    Downside

    6.14%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $19.05
    $26.58
    downward going graph

    20.39%

    Downside

    11.07%

    Upside

    downward going graph

Catalyst Pharmaceuticals Inc share price movements today

Previous Close
$25.06
Open
$25.22
Volume
1.0M
Day's Low - High
$23.86 - $25.40
52 Week Low - High
$19.05 - $26.58

Catalyst Pharmaceuticals Inc Historical Returns

1 Month Return
+ 5.89 %
3 Month Return
+ 13.91 %
1 Year Return
+ 3.69 %
3 Year Return
+ 50.66 %
5 Year Return
+ 447.14 %

Catalyst Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Catalyst Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.9B

EPS (TTM)

2.5417

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.20%

PE Ratio (TTM)

14.03

Industry PE ratio

5.581153846153846

PEG Ratio

0

EBITDA

296.6M

Revenue (TTM)

578.2M

Profit Margin

37.63%

Return On Equity TTM

27.52%

Catalyst Pharmaceuticals Inc Stock Valuation

Track how Catalyst Pharmaceuticals Inc P/E has moved over time to understand its valuation trends.

Catalyst Pharmaceuticals Inc in the last 5 years

  • Overview

  • Trends

Lowest (10.45x)

March 31, 2021

Industry (5.58x)

February 6, 2026

Today (14.03x)

February 6, 2026

Highest (28.83x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 14.03x

Catalyst Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Catalyst Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Catalyst Pharmaceuticals Inc image
Catalyst Pharmaceuticals Inc
BUY$2.9B447.14%14.0337.63%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$47.7B100.62%1246.031.36%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$122.3B113.14%33.5631.35%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$37.4BNA662.331.38%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.8B53.64%18.2832.13%

Stock Returns calculator for Catalyst Pharmaceuticals Inc Stock including INR - Dollar returns

The Catalyst Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Catalyst Pharmaceuticals Inc investment value today

Current value as on today

₹1,07,141

Returns

₹7,141

(+7.14%)

Returns from Catalyst Pharmaceuticals Inc Stock

₹3,773 (+3.77%)

Dollar Returns*

₹3,368 (+3.37%)

Analyst Recommendation on Catalyst Pharmaceuticals Inc Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.31% of analysts recommend a 'BUY' rating for Catalyst Pharmaceuticals Inc. Average target price of $34.57

Catalyst Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Catalyst Pharmaceuticals Inc.

What analysts predicted

30.78%UPSIDE

Target Price

$34.57

Current Price

$23.93

Analyzed by

13 Analysts

Target

$34.57

Catalyst Pharmaceuticals Inc target price $34.57, a slight upside of 30.78% compared to current price of $23.93. According to 13 analysts rating.

Catalyst Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Catalyst Pharmaceuticals Inc Stock has increased by 55% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:55% versus previous 30 day period

Catalyst Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
99
102
110
98
122
128
141
141
146
148
Gross Profit
87
88
94
85
107
109
120
123
116
123
Operating Income
46
-37
41
27
54
50
62
63
66
66
EBITDA
55
-28
50
36
63
50
72
72
78
80
Interest Expense
-
0
1
-
-
-
-
-
-
-
Depreciation
8
8
9
9
9
9
9
9
9
9
Income Before Tax
48
-38
46
29
55
57
74
71
69
71
Income Tax Expense
10
-7
11
5
14
13
18
14
17
18
Net Income
37
-30
34
23
40
43
55
56
52
52
Net Profit Margin
37.92%
-29.96%
31.51%
23.63%
33.24%
34.10%
39.44%
40.12%
35.55%
35.57%

Catalyst Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
0
102
119
140
214
398
491
Gross Profit
0
0
0
0
87
102
118
179
346
422
Operating Income
-20
-19
-18
-35
31
41
52
101
86
195
EBITDA
-20
-18
-18
-35
32
42
52
103
119
232
Interest Expense
0
0
0
1
1
1
0
4
-
-
Depreciation
-
-
0
0
0
0
0
1
24
37
Income Before Tax
-20
-18
-18
-34
33
41
52
104
94
216
Income Tax Expense
0
0
0
2
1
-33
13
21
23
52
Net Income
-20
-18
-18
-34
31
74
39
83
71
163
Net Profit Margin
0.00%
0.00%
0.00%
-6800.70%
31.16%
62.97%
28.03%
38.79%
17.93%
33.33%

Catalyst Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-30
34
23
40
43
55
56
52
52
Operating Cash Flow
45
55
31
64
72
70
60
71
32
Investing Cash Flow
-92
-38
0
0
0
0
-
0
-
Financing Cash Flow
-10
0
141
1
-5
4
3
0
4
Change in Cash
-57
16
172
65
66
75
63
72
37

Catalyst Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-18
-18
-34
31
74
39
83
71
163
Operating Cash Flow
-17
-13
-25
34
45
60
116
143
239
Investing Cash Flow
3
0
-15
37
-5
-11
9
-293
0
Financing Cash Flow
0
57
0
1
0
-8
1
-10
140
Change in Cash
-14
43
-40
72
40
41
126
-160
379

Global Institutional Holdings in Catalyst Pharmaceuticals Inc

Funds
Holdings
Geode Capital Management, LLC
2.34%
American Century Companies Inc
1.44%
Allianz Asset Management AG
0.85%
Qube Research & Technologies
0.83%
Vanguard Group Inc
7.16%
See all

Insights on Catalyst Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 141.42M → 148.39M (in $), with an average increase of 2.4% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 52.10M → 52.78M (in $), with an average increase of 1.3% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CPRX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, CPRX stock has moved up by 5.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 51.6% return, outperforming this stock by 47.9%

About Catalyst Pharmaceuticals Inc

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
OrganisationCatalyst Pharmaceuticals Inc
Headquarters355 Alhambra Circle, Coral Gables, FL, United States, 33134
IndustryHealth Technology
CEOMr. Richard John Daly M.B.A.
E-voting on sharesClick here to vote

Key Management of Catalyst Pharmaceuticals Inc

Name

Title

Mr. Philip B. Schwartz Esq.

Corporate Secretary

Mr. Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Dr. William T. Andrews FACP, M.D.

Chief Medical Officer

Dr. Steven R. Miller Ph.D.

Executive VP, COO & Chief Scientific Officer

Mr. Jeffrey Del Carmen

Executive VP & Chief Commercial Officer

Dr. Preethi Sundaram Ph.D.

Chief Strategy Officer

Ms. Mary Coleman

VP & Head of Investor Relations

Mr. Gregg Russo

Chief Human Resources Officer

Mr. Richard John Daly M.B.A.

President, CEO & Director

Mr. Michael W. Kalb CPA

Executive VP, Treasurer & CFO

FAQs

What is Catalyst Pharmaceuticals Inc share price today?

Catalyst Pharmaceuticals Inc share price today is $23.93 as on at the close of the market. Catalyst Pharmaceuticals Inc share today touched a day high of $25.4 and a low of $23.86.

What is the 52 week high and 52 week low for Catalyst Pharmaceuticals Inc share?

Catalyst Pharmaceuticals Inc share touched a 52 week high of $26.58 on and a 52 week low of $19.05 on . Catalyst Pharmaceuticals Inc stock price today i.e. is closed at $23.93,which is 9.97% down from its 52 week high and 25.62% up from its 52 week low.

What is Catalyst Pharmaceuticals Inc's market capitalisation today?

Catalyst Pharmaceuticals Inc market capitalisation is $0.00T as on .

How to invest in Catalyst Pharmaceuticals Inc Stock (CPRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Catalyst Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Catalyst Pharmaceuticals Inc Shares that will get you 0.0627 shares as per Catalyst Pharmaceuticals Inc share price of $23.93 per share as on February 6, 2026 at 2:29 am IST.

What is the minimum amount required to buy Catalyst Pharmaceuticals Inc Stock (CPRX) from India?

Indian investors can start investing in Catalyst Pharmaceuticals Inc (CPRX) shares with as little as ₹90.283 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹902.83 in Catalyst Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Catalyst Pharmaceuticals Inc share’s latest price of $23.93 as on February 6, 2026 at 2:29 am IST, you will get 0.4179 shares of Catalyst Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Catalyst Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Catalyst Pharmaceuticals Inc stock has given 447.14% share price returns and 25.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?